Literature DB >> 15026413

Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease.

Makoto Hashimoto1, Pazit Bar-On, Gilbert Ho, Takato Takenouchi, Edward Rockenstein, Leslie Crews, Eliezer Masliah.   

Abstract

Recent studies have shown that the neurodegenerative process in disorders with Lewy body formation, such as Parkinson's disease and dementia with Lewy bodies, is associated with alpha-synuclein accumulation and that beta-synuclein might protect the central nervous system from the neurotoxic effects of alpha-synuclein. However, the mechanisms are unclear. The main objective of the present study was to investigate the potential involvement of the serine threonine kinase Akt (also known as protein kinase B) signaling pathway in the mechanisms of beta-synuclein neuroprotection. For this purpose, Akt activity and cell survival were analyzed in synuclein-transfected B103 neuroblastoma cells and primary cortical neurons. Beta-synuclein transfection resulted in increased Akt activity and conferred protection from the neurotoxic effects of rotenone. Down-regulation of Akt expression resulted in an increased susceptibility to rotenone toxicity, whereas transfection with a lentiviral vector encoding for beta-synuclein was protective. The effects of beta-synuclein on the Akt pathway appear to be by direct interaction between these molecules and were independent of upstream signaling molecules. Taken together, these results indicate that the mechanisms of beta-synuclein neuroprotection might involve direct interactions between beta-synuclein and Akt and suggest that this signaling pathway could be a potential therapeutic target for neurological conditions associated with parkinsonism and alpha-synuclein aggregation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15026413     DOI: 10.1074/jbc.M313784200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Protein aggregation in retinal cells and approaches to cell protection.

Authors:  Irina Surgucheva; Natalia Ninkina; Vladimir L Buchman; Kenneth Grasing; Andrei Surguchov
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

Review 2.  Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models.

Authors:  Ruben K Dagda; Jianhui Zhu; Charleen T Chu
Journal:  Mitochondrion       Date:  2009-06-27       Impact factor: 4.160

3.  Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment.

Authors:  Lloyd A Greene; Oren Levy; Cristina Malagelada
Journal:  Cell Mol Neurobiol       Date:  2011-03-10       Impact factor: 5.046

4.  PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway.

Authors:  Ruth Mélida Sánchez-Mora; Humberto Arboleda; Gonzalo Arboleda
Journal:  J Mol Neurosci       Date:  2012-01-03       Impact factor: 3.444

Review 5.  The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.

Authors:  Makoto Hashimoto; Kohichi Kawahara; Pazit Bar-On; Edward Rockenstein; Leslie Crews; Eliezer Masliah
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Effects of maternal separation and methamphetamine exposure on protein expression in the nucleus accumbens shell and core.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-28       Impact factor: 3.584

Review 7.  The Role of PI3K/Akt and ERK in Neurodegenerative Disorders.

Authors:  Sachchida Nand Rai; Hagera Dilnashin; Hareram Birla; Saumitra Sen Singh; Walia Zahra; Aaina Singh Rathore; Brijesh Kumar Singh; Surya Pratap Singh
Journal:  Neurotox Res       Date:  2019-02-01       Impact factor: 3.911

Review 8.  Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Authors:  Masayo Fujita; Akio Sekigawa; Kazunari Sekiyama; Shuei Sugama; Makoto Hashimoto
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

9.  Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation.

Authors:  Zengxia Ma; Jianyi Niu; Erlian Sun; Xuedong Rong; Xianxin Zhang; Yuanrong Ju
Journal:  Tumour Biol       Date:  2016-09-22

10.  Beta-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with alpha-synuclein.

Authors:  Eitan Israeli; Ronit Sharon
Journal:  J Neurochem       Date:  2008-12-02       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.